Docetaxel plus SX-682 for advanced head and neck or prostate cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Kidney & urinary, Lungs & breathing, Mouth & dental clinical trials.
This trial studies a combination of the chemotherapy drug docetaxel and an investigational drug called SX-682 for people with certain advanced head and neck cancers or prostate cancer. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be able to take care of yourself (up to some help with daily activities).
- Your liver, kidneys, and blood counts must be within acceptable limits.
- You must be willing to use effective birth control during and after treatment.
- You must be able to swallow oral medications.
- For head and neck cancer: you must have had prior systemic treatment (chemotherapy or immunotherapy).
- For prostate cancer: you must have had prior treatment with modern anti-androgens like abiraterone or enzalutamide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
This trial tests a new targeted drug (SYS6010) compared with standard single-drug treatments for advanced head and neck cancer that has not responded to previous therapies. The goal is to see if this new drug can shrink tumors or slow cancer growth better than the usual options.
This study tests whether adding a chemotherapy drug called docetaxel to radiation therapy helps treat head and neck cancer better than radiation alone. It also checks the side effects. This might be an option if your cancer is locally advanced and has not spread.
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.